Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies

Journal of Nuclear Medicine

Volumn 46, Issue 4, 2005, Pages 642-651

  Shen, Sui ^a,e   Forero, Andres ^b   LoBuglio, Albert F ^b   Breitz, Hazel ^c   Khazaeli, M B ^a   Fisher, Darrell R ^d   Wang, Wenquan ^a   Meredith, Ruby F ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^e The University of Alabama at Birmingham   (United States)

Author keywords

Dosimetry; Gastrointestinal cancer; Pretargeted radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN; HYBRID PROTEIN; PROTEIN CC49; RADIOISOTOPE; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90; B72.3 ANTIBODY; CANCER ANTIBODY; DOTA BIOTIN; DOTA-BIOTIN; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSIMETRY; HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; WHOLE BODY SCINTISCANNING; ANTIBODY SPECIFICITY; BODY BURDEN; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; FEMALE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; RADIOMETRY; RELATIVE BIOLOGIC EFFECTIVENESS; TISSUE DISTRIBUTION;

AGED; ANTIBODIES, NEOPLASM; BIOTIN; BODY BURDEN; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECOMBINANT FUSION PROTEINS; RELATIVE BIOLOGICAL EFFECTIVENESS; TISSUE DISTRIBUTION;

EID: 19644371098     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 131I Lym-1 monoclonal antibodies. Int J Cancer. 1988;3(suppl):96-101.
2. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993; 329:1219-1224.
3. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329: 459-465.
4. 90Y-ZeValin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766-777.
5. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 1995;36:586-592.
6. Murray JL, Macey DJ, Grant EJ, et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res. 1995;55(suppl):5925-5928.
7. Tempero M, Leichner P, Dalrymple G, et al. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial. J Clin Oncol. 1997;15:1518-1528.
8. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res. 1996;2:1811-1818.
9. 90yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000;6:3095-3102.
10. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999;14:381-395.
11. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000;6:406-414.
12. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29.
13. 90Y-DOTA-biotin. J Nucl Med. 2000;41:131-140.
14. Weiden PL, Breitz HB. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit Rev Oncol Hematol. 2001;40:37-51.
15. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
16. Forero A, Weiden PL, Vose JM, et al. Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood. 2004;104:227-236.
17. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;3:253-255.
18. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys. 1994;21:1409-1417.
19. DeNardo GL, Shen S, DeNardo SJ, et al. Quantification of iodine-131 in tumors using a threshold based on image contrast. Eur J Nucl Med. 1998;25:497-502.
20. Loevinger R, Bermam M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides. MIRD Pamphlet No. 1. New York, NY: Society of Nuclear Medicine; 1976.
21. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media: MIRD Pamphlet No. 7. J Nucl Med. 1971;5(suppl):5-23.
22. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152-156.
23. Shen S, DeNardo GL, O'Donnell RT, et al. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer. 1997;80:2553-2557.
24. Shen S, DeNardo GL, Sgouros G, et al. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med. 1999;40:2102-2106.
25. Dillman L, Von der Lage F. Radionuclide Decay Schemes and Nuclear Parameters/or Use in Radiation-Dose Estimation. MIRD Pamphlet No. 10. New York, NY: Society of Nuclear Medicine; 1975.
26. Snyder WS, Ford MR, Warner GG, Watson SB. 'S', Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11. New York, NY: Society of Nuclear Medicine; 1975.
27. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
28. Snyder WS, Fisher HL Jr, Ford MR, Warner GG. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med. 1969;3(suppl):7-52.
29. Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immuno-histochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res. 1990;50:1291-1298.
30. Leichner PK, Akabani G, Colcher D, et al. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997;38: 512-516.
31. Meredith R, Shen S, Macey D, et al. Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm. 2003;18:393-404.
32. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
33. Huh C, Bolch WE. A review of US anthropometric reference data (1971-2000) with comparisons to both stylized and tomographic anatomic models. Phys Med Biol. 2003;48:3411-3429.
34. 86Y-antibody therapy. J Nucl Med. 2002;43:1245-1253.
35. 111In radiolabels. J Nucl Med. 2001;42:1281-1287.